RIGOR guidelines: escalating STAIR and STEPS for effective translational research - Wikidata - awgldk - TriplyDB

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

http://www.wikidata.org/entity/Q36816551

about

The methodological quality of animal research in critical care: the public face of science Regulatory T cell in stroke: a new paradigm for immune regulation Poised for success: implementation of sound conditioning strategies to promote endogenous protective responses to stroke in patients Sustained functional improvement by hepatocyte growth factor-like small molecule BB3 after focal cerebral ischemia in rats and mice.Hyperbaric oxygen modalities are differentially effective in distinct brain ischemia models Shining light on the head: Photobiomodulation for brain disorders Neurovascular events after subarachnoid hemorrhage: focusing on subcellular organelles Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers 2013 Thomas Willis Award Lecture: Causation and collaboration for stroke research.Evidence for Decreased Brain Parenchymal Volume After Large Intracerebral Hemorrhages: a Potential Mechanism Limiting Intracranial Pressure Rises.Vascular neural network in subarachnoid hemorrhage.Improving the translation of animal ischemic stroke studies to humans.Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke.Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats.A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.A blinded, randomized study of L-arginine in small clot embolized rabbits Transcranial Near-Infrared Laser Transmission (NILT) Profiles (800 nm): Systematic Comparison in Four Common Research Species G-CSF attenuates neuroinflammation and stabilizes the blood-brain barrier via the PI3K/Akt/GSK-3β signaling pathway following neonatal hypoxia-ischemia in rats.Translational intracerebral hemorrhage: a need for transparent descriptions of fresh tissue sampling and preclinical model quality Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection.Critical role of sphingosine-1-phosphate receptor-2 in the disruption of cerebrovascular integrity in experimental stroke Evolution of ischemic damage and behavioural deficit over 6 months after MCAo in the rat: Selecting the optimal outcomes and statistical power for multi-centre preclinical trials Data Standardization and Quality Management.Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now.Progesterone improves long-term functional and histological outcomes after permanent stroke in older rats.Effects of tissue plasminogen activator and annexin A2 combination therapy on long-term neurological outcomes of rat focal embolic stroke.Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need.Controversies and evolving new mechanisms in subarachnoid hemorrhage.Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.Vascular neural network: the importance of vein drainage in stroke.Effects of delayed puerarin treatment in long-term neurological outcomes of focal ischemic stroke in rats.Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models Correcting for Brain Swelling's Effects on Infarct Volume Calculation After Middle Cerebral Artery Occlusion in Rats.Preclinical neuroprotective actions of xenon and possible implications for human therapeutics: a narrative review.How do researchers decide early clinical trials?Inhibition of neuronal ferroptosis protects hemorrhagic brain

P2860

Q24288845-EB4E524E-A98A-439F-9E40-7B7B2E09C974 Q26995751-DEC28FDF-1283-4398-BBC1-AEEAAE5A8BCB Q27012735-3DC86F71-A03A-4352-B0F3-A999BCA16E43 Q27321286-CE64631F-A5E0-4B63-977A-1116EF914281 Q28068754-D11CA425-A4F9-4E65-9A8F-B4F72751B7F5 Q28078596-D375269A-3881-4ADA-954C-F0119C48B088 Q28390515-56A9D3EB-6297-4B77-907E-071EC0AB063B Q33693490-CAD53C11-2102-41E6-92F9-88FF490F9E62 Q33793133-F500035B-DCA2-4847-AF74-A2A187A025D4 Q33861271-84377BF2-D635-4573-9183-C49E0AFCB3DA Q34023830-DB453D99-1B42-4AB8-9BD7-02D4FEC4AAA9 Q34294669-399C13B1-78B4-4D9F-931B-A4AA8852B2EC Q34432486-D1308C4D-BB05-492D-9A1A-A602BAC5E70B Q34982356-EB1DA20B-B3AE-4C68-ABC5-1BBA38306753 Q35175537-C8EAAF5F-75CB-4328-8003-A4659D84CD71 Q35225903-017E5D95-F151-4E10-AB09-4922D0F986A3 Q35243300-60315AF4-9140-440E-BBA8-71E0E29F20E7 Q35651274-BF3BEEBC-81D5-4B3D-AFE3-41C3447648B5 Q35842220-8EF65E05-AF9B-4627-81CB-516B476D8011 Q36030687-2C37F948-29DE-4A2E-B476-F2F7CBA72ECC Q36056147-1E9C4523-6524-40C9-A0B5-B8B09C77AD02 Q36104426-AED61207-4693-4BB9-AD82-EBDADE24F8AB Q36275582-A68F11D1-AB51-496E-84AA-08359CC081A9 Q36304995-B99FD56E-8FD7-433D-90AF-94AFEB8CDE0B Q36522091-67FFEF04-7FB4-44AF-930C-6B6066A6104D Q36540005-3039E768-B660-4B6B-A56D-AFA09502237F Q36614594-4A3EF747-7B98-459F-B362-9C73C299F660 Q37420266-BAA4E63D-421E-418E-BC18-8F817E24F3BE Q37460898-43D421E4-3D77-4462-ABEE-B8CBF01A703C Q37549827-DE93D0CE-5718-44D1-ADD1-3D194BBDD593 Q37640874-3CC450E4-51AB-4E40-B8D3-4C7A369195FA Q37652820-55916A07-00F5-4D45-9BEB-4F1798D540C4 Q37670794-B85655A4-5493-49EB-BA80-2513EC5B1E28 Q37701135-3DDBED75-9C6C-4F49-B382-DC2555BBC38B Q37703544-FAABC5C4-3191-4EFA-BDC4-2E5292EF1A54 Q37716837-B298C7C8-7949-4908-8B1D-08A647B18859 Q38612026-6AADC81E-6D54-4DE5-BEE1-1F7CF8AC5B24 Q38617718-6F51D04A-5111-416E-A170-27596CDE0C1A Q38718855-157D0ED9-FF88-4413-B7AA-CE8A51676F3B Q38730939-5840CD13-4817-462F-8523-D62AF1AB419A

P2860

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

http://www.wikidata.org/entity/Q36816551

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@ast

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@en

type

label

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@ast

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@en

prefLabel

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@ast

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@en

P1433

Q36816551-BB97374F-0A55-40DC-9A8E-6855ED0F7A2E

P1476

Q36816551-B2994276-DEFA-48F2-9B2E-F78CC5F950DE

P2093

Q36816551-595DA6C3-FA9D-418F-A665-CD0F02E8C998

Q36816551-E107CD5E-639F-49BC-9256-7F269B8377CC

P2860

Q36816551-00E54ACE-FE14-487C-9A72-D5F4EFFD234A

Q36816551-0E9C247F-3519-4A3C-B2E2-4132DAE9C9E8

Q36816551-11BD7FED-6B4D-4513-AF8B-B70A463FAE5D

Q36816551-12C0714A-3D87-4AA0-9920-DA3DB3753644

Q36816551-14F54596-8C61-40EC-BDEB-E3704AEE1A45

Q36816551-2102DB80-5993-499E-B756-C0F7FFA76479

Q36816551-272ECE3D-38BB-4729-937C-A1C851CB312B

Q36816551-27514CC4-1AF9-4D6D-935B-0D5B08CF483B

Q36816551-297D6BBB-EC7C-4CB7-A92C-243D17A27E06

Q36816551-39112BC7-1D2F-439D-9D3E-BA863323642A

P2888

Q36816551-308682D7-DA20-41C6-8E3B-F5A2443EDAAF

P304

Q36816551-4E3F11DB-555D-4D9B-968F-2809989C327C

P31

Q36816551-7CC5FE17-CCCF-4A0E-B918-6D6E7247F90A

P356

Q36816551-597700D1-A694-43D5-A2F5-CBEC95617BEE

P433

Q36816551-4E250BB3-336D-4C13-B1BF-F17F27383098

P478

Q36816551-BB9DDB21-CB65-4BDF-BB0C-C1513487BF50

P50

Q36816551-A7605650-A126-4F60-AD86-5AD4C8656E1E

P577

Q36816551-35C46707-B2A0-4818-931F-DB70F04C1DD6

P5875

Q36816551-848BB578-B153-405A-82AB-3E4F911CF5BF

P698

Q36816551-5747A39B-C8C5-4701-A5D8-A8FA015DA13B

P932

Q36816551-B1F1A231-4F63-45EF-BDEA-DD4DD512AEA0

P356

S12975-012-0209-2

P1433

Translational stroke research

P1476

RIGOR guidelines: escalating STAIR and STEPS for effective translational research

@en

P2093

John H Zhang

http://www.w3.org/2001/XMLSchema#string

Linda J Noble-Haeusslein

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial

Spontaneous Sub-arachnoid Haemorrhage

Effects of NXY-059 in experimental stroke: an individual animal meta-analysis

Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials

Nonhuman primate models of stroke for translational neuroprotection research.

Subarachnoid haemorrhage

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

P2888

s12975-012-0209-2

P304

279-285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12975-012-0209-2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Paul A. Lapchak

P577

2012-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236666636

http://www.w3.org/2001/XMLSchema#string

P698

23658596

http://www.w3.org/2001/XMLSchema#string

P932

3644408

http://www.w3.org/2001/XMLSchema#string